William Blair lowered their Q3 2025 EPS estimates for ResMed in a research report issued on Monday, February 3rd. William Blair analyst M. Andrew now anticipates that the medical equipment provider ...

Shares of ResMed Inc. RMD shed 2.23% to $237.18 Thursday, on what proved to be an all-around mixed trading session for the ...

An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) is now available. ResMed Inc has ...

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter. The post Looking to bag the record high ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed (RMD – Research Report), with a price target of ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

Here's why these ASX 200 blue chip shares could be top options for a $2,000 investment in February. Let's find out ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability. The great quarter was driven by high ...